Trial Profile
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary)
- Indications Angioedema
- Focus Adverse reactions; Therapeutic Use
- Sponsors Dyax; Shire
- 05 Jun 2014 New trial record